Clinical studies on TMS-19-Q • o tablet in respiratory tract infection

Kohei Hara; Kinichi Izumikawa; Yoji Suzuyama; Yoshiteru Shigeno; Munetaka Komori; Hiroshi Tomita; Masao Sai; Akira Ikebe; Hiromaru Iwasaki; Akira Saito; Masumi Tomizawa; Ichiro Nakayama; Seiichi Aonuma; Kikuo Onuma; Akira Watanabe; Masako Sasaki; Kotaro Oizumi; Kiyoshi Konno; Kosaku Nagai; Izumi Hayashi; Tatsuya Abe; Osamu Sekine; Yoshimaru Usuda; Nobuki Aoki; Yasuko Yuasa; Isao Nitta; Kyoko Watanabe; Fusanosuke Yamasaku; Yasutoshi Suzuki; Masataka Katsu; Shinji Okui; Otohiko Kunii; Takashi Komatsu; Hajime Nishiya; Kohya Shiba; Atsushi Saito; Tadashi Miyahara; Keimei Mashimo; Sumio Yamaoka; Keiichi Nakagawa; Masaru Koyama; Teppei Kumada; Hiroyuki Kobayashi; Hiroaki Takeda; Tomoko Nihei; Mitsuo Obana; Yoshio Kobayashi; Ippei Fujimori; Akira Ito; Masanori Matsumura; Kunihiko Shindo; Kokichi Fukushima; Shigeki Odagiri; Makio Kurihara; Hideyuki Hasegawa; Fumio Matsumoto; Masahito Kato; Joichi Kato; Kazuo Yoshitomo; Motoko Yamamoto; Saburo Kitaura; Hidekazu Hanaki; Yoshiyuki Yamamoto; Toshihiko Takeuchi; Fumio Miki; Kenji Takamatsu; Masakazu Kohno; Yuruko Okamoto; Keigo Maehara; Kanshi Mase; Yube Iida; Muneto Yoshioka; Kojiro Yasunaga; Yoshihiro Ueda; Hiroshi Ohkubo; Rinzo Soejima; Yoshito Niki; Masayoshi Kawanishi; Chikara Nakahama; Masatoshi Watanabe; Jiro Hino; Masakazu Tamura; Toshihiro Goto; Yoshihiro Takishita; Eiro Tsubura; Yoshiro Sawae; Kaoru Okada; Yukio Kumagai; Keizo Matsumoto; Yoshio Uzuka; Naoto Rikitomi; Yasutsugu Fukuda; Katsumasa Tokunaga; Masayuki Ando; Haruhiko Tokuomi

doi:10.11553/antibiotics1968b.38.553

Clinical studies on TMS-19-Q • o tablet in respiratory tract infection

Kohei Hara, Kinichi Izumikawa, Yoji Suzuyama, Yoshiteru Shigeno, Munetaka Komori, Hiroshi Tomita, Masao Sai, Akira Ikebe, Hiromaru Iwasaki, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Seiichi Aonuma, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai, Izumi HayashiTatsuya Abe, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Yasuko Yuasa, Isao Nitta, Kyoko Watanabe, Fusanosuke Yamasaku, Yasutoshi Suzuki, Masataka Katsu, Shinji Okui, Otohiko Kunii, Takashi Komatsu, Hajime Nishiya, Kohya Shiba, Atsushi Saito, Tadashi Miyahara, Keimei Mashimo, Sumio Yamaoka, Keiichi Nakagawa, Masaru Koyama, Teppei Kumada, Hiroyuki Kobayashi, Hiroaki Takeda, Tomoko Nihei, Mitsuo Obana, Yoshio Kobayashi, Ippei Fujimori, Akira Ito, Masanori Matsumura, Kunihiko Shindo, Kokichi Fukushima, Shigeki Odagiri, Makio Kurihara, Hideyuki Hasegawa, Fumio Matsumoto, Masahito Kato, Joichi Kato, Kazuo Yoshitomo, Motoko Yamamoto, Saburo Kitaura, Hidekazu Hanaki, Yoshiyuki Yamamoto, Toshihiko Takeuchi, Fumio Miki, Kenji Takamatsu, Masakazu Kohno, Yuruko Okamoto, Keigo Maehara, Kanshi Mase, Yube Iida, Muneto Yoshioka, Kojiro Yasunaga, Yoshihiro Ueda, Hiroshi Ohkubo, Rinzo Soejima, Yoshito Niki, Masayoshi Kawanishi, Chikara Nakahama, Masatoshi Watanabe, Jiro Hino, Masakazu Tamura, Toshihiro Goto, Yoshihiro Takishita, Eiro Tsubura, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Keizo Matsumoto, Yoshio Uzuka, Naoto Rikitomi, Yasutsugu Fukuda, Katsumasa Tokunaga, Masayuki Ando, Haruhiko Tokuomi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.

Original language	English
Pages (from-to)	553-574
Number of pages	22
Journal	The Japanese Journal of Antibiotics
Volume	38
Issue number	3
DOIs	https://doi.org/10.11553/antibiotics1968b.38.553
Publication status	Published - 1985
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.38.553

Cite this

Hara, K., Izumikawa, K., Suzuyama, Y., Shigeno, Y., Komori, M., Tomita, H., Sai, M., Ikebe, A., Iwasaki, H., Saito, A., Tomizawa, M., Nakayama, I., Aonuma, S., Onuma, K., Watanabe, A., Sasaki, M., Oizumi, K., Konno, K., Nagai, K., ... Tokuomi, H. (1985). Clinical studies on TMS-19-Q • o tablet in respiratory tract infection. The Japanese Journal of Antibiotics, 38(3), 553-574. https://doi.org/10.11553/antibiotics1968b.38.553

Clinical studies on TMS-19-Q • o tablet in respiratory tract infection. / Hara, Kohei; Izumikawa, Kinichi; Suzuyama, Yoji; Shigeno, Yoshiteru; Komori, Munetaka; Tomita, Hiroshi; Sai, Masao; Ikebe, Akira; Iwasaki, Hiromaru; Saito, Akira; Tomizawa, Masumi; Nakayama, Ichiro; Aonuma, Seiichi; Onuma, Kikuo; Watanabe, Akira; Sasaki, Masako; Oizumi, Kotaro; Konno, Kiyoshi; Nagai, Kosaku; Hayashi, Izumi; Abe, Tatsuya; Sekine, Osamu; Usuda, Yoshimaru; Aoki, Nobuki; Yuasa, Yasuko; Nitta, Isao; Watanabe, Kyoko; Yamasaku, Fusanosuke; Suzuki, Yasutoshi; Katsu, Masataka; Okui, Shinji; Kunii, Otohiko; Komatsu, Takashi; Nishiya, Hajime; Shiba, Kohya; Saito, Atsushi; Miyahara, Tadashi; Mashimo, Keimei; Yamaoka, Sumio; Nakagawa, Keiichi; Koyama, Masaru; Kumada, Teppei; Kobayashi, Hiroyuki; Takeda, Hiroaki; Nihei, Tomoko; Obana, Mitsuo; Kobayashi, Yoshio; Fujimori, Ippei; Ito, Akira; Matsumura, Masanori; Shindo, Kunihiko; Fukushima, Kokichi; Odagiri, Shigeki; Kurihara, Makio; Hasegawa, Hideyuki; Matsumoto, Fumio; Kato, Masahito; Kato, Joichi; Yoshitomo, Kazuo; Yamamoto, Motoko; Kitaura, Saburo; Hanaki, Hidekazu; Yamamoto, Yoshiyuki; Takeuchi, Toshihiko; Miki, Fumio; Takamatsu, Kenji; Kohno, Masakazu; Okamoto, Yuruko; Maehara, Keigo; Mase, Kanshi; Iida, Yube; Yoshioka, Muneto; Yasunaga, Kojiro; Ueda, Yoshihiro; Ohkubo, Hiroshi; Soejima, Rinzo; Niki, Yoshito; Kawanishi, Masayoshi; Nakahama, Chikara; Watanabe, Masatoshi; Hino, Jiro; Tamura, Masakazu; Goto, Toshihiro; Takishita, Yoshihiro; Tsubura, Eiro; Sawae, Yoshiro; Okada, Kaoru; Kumagai, Yukio; Matsumoto, Keizo; Uzuka, Yoshio; Rikitomi, Naoto; Fukuda, Yasutsugu; Tokunaga, Katsumasa; Ando, Masayuki; Tokuomi, Haruhiko.

In: The Japanese Journal of Antibiotics, Vol. 38, No. 3, 1985, p. 553-574.

Research output: Contribution to journal › Article › peer-review

Hara, K, Izumikawa, K, Suzuyama, Y, Shigeno, Y, Komori, M, Tomita, H, Sai, M, Ikebe, A, Iwasaki, H, Saito, A, Tomizawa, M, Nakayama, I, Aonuma, S, Onuma, K, Watanabe, A, Sasaki, M, Oizumi, K, Konno, K, Nagai, K, Hayashi, I, Abe, T, Sekine, O, Usuda, Y, Aoki, N, Yuasa, Y, Nitta, I, Watanabe, K, Yamasaku, F, Suzuki, Y, Katsu, M, Okui, S, Kunii, O, Komatsu, T, Nishiya, H, Shiba, K, Saito, A, Miyahara, T, Mashimo, K, Yamaoka, S, Nakagawa, K, Koyama, M, Kumada, T, Kobayashi, H, Takeda, H, Nihei, T, Obana, M, Kobayashi, Y, Fujimori, I, Ito, A, Matsumura, M, Shindo, K, Fukushima, K, Odagiri, S, Kurihara, M, Hasegawa, H, Matsumoto, F, Kato, M, Kato, J, Yoshitomo, K, Yamamoto, M, Kitaura, S, Hanaki, H, Yamamoto, Y, Takeuchi, T, Miki, F, Takamatsu, K, Kohno, M, Okamoto, Y, Maehara, K, Mase, K, Iida, Y, Yoshioka, M, Yasunaga, K, Ueda, Y, Ohkubo, H, Soejima, R, Niki, Y, Kawanishi, M, Nakahama, C, Watanabe, M, Hino, J, Tamura, M, Goto, T, Takishita, Y, Tsubura, E, Sawae, Y, Okada, K, Kumagai, Y, Matsumoto, K, Uzuka, Y, Rikitomi, N, Fukuda, Y, Tokunaga, K, Ando, M & Tokuomi, H 1985, 'Clinical studies on TMS-19-Q • o tablet in respiratory tract infection', The Japanese Journal of Antibiotics, vol. 38, no. 3, pp. 553-574. https://doi.org/10.11553/antibiotics1968b.38.553

Hara, Kohei ; Izumikawa, Kinichi ; Suzuyama, Yoji ; Shigeno, Yoshiteru ; Komori, Munetaka ; Tomita, Hiroshi ; Sai, Masao ; Ikebe, Akira ; Iwasaki, Hiromaru ; Saito, Akira ; Tomizawa, Masumi ; Nakayama, Ichiro ; Aonuma, Seiichi ; Onuma, Kikuo ; Watanabe, Akira ; Sasaki, Masako ; Oizumi, Kotaro ; Konno, Kiyoshi ; Nagai, Kosaku ; Hayashi, Izumi ; Abe, Tatsuya ; Sekine, Osamu ; Usuda, Yoshimaru ; Aoki, Nobuki ; Yuasa, Yasuko ; Nitta, Isao ; Watanabe, Kyoko ; Yamasaku, Fusanosuke ; Suzuki, Yasutoshi ; Katsu, Masataka ; Okui, Shinji ; Kunii, Otohiko ; Komatsu, Takashi ; Nishiya, Hajime ; Shiba, Kohya ; Saito, Atsushi ; Miyahara, Tadashi ; Mashimo, Keimei ; Yamaoka, Sumio ; Nakagawa, Keiichi ; Koyama, Masaru ; Kumada, Teppei ; Kobayashi, Hiroyuki ; Takeda, Hiroaki ; Nihei, Tomoko ; Obana, Mitsuo ; Kobayashi, Yoshio ; Fujimori, Ippei ; Ito, Akira ; Matsumura, Masanori ; Shindo, Kunihiko ; Fukushima, Kokichi ; Odagiri, Shigeki ; Kurihara, Makio ; Hasegawa, Hideyuki ; Matsumoto, Fumio ; Kato, Masahito ; Kato, Joichi ; Yoshitomo, Kazuo ; Yamamoto, Motoko ; Kitaura, Saburo ; Hanaki, Hidekazu ; Yamamoto, Yoshiyuki ; Takeuchi, Toshihiko ; Miki, Fumio ; Takamatsu, Kenji ; Kohno, Masakazu ; Okamoto, Yuruko ; Maehara, Keigo ; Mase, Kanshi ; Iida, Yube ; Yoshioka, Muneto ; Yasunaga, Kojiro ; Ueda, Yoshihiro ; Ohkubo, Hiroshi ; Soejima, Rinzo ; Niki, Yoshito ; Kawanishi, Masayoshi ; Nakahama, Chikara ; Watanabe, Masatoshi ; Hino, Jiro ; Tamura, Masakazu ; Goto, Toshihiro ; Takishita, Yoshihiro ; Tsubura, Eiro ; Sawae, Yoshiro ; Okada, Kaoru ; Kumagai, Yukio ; Matsumoto, Keizo ; Uzuka, Yoshio ; Rikitomi, Naoto ; Fukuda, Yasutsugu ; Tokunaga, Katsumasa ; Ando, Masayuki ; Tokuomi, Haruhiko. / Clinical studies on TMS-19-Q • o tablet in respiratory tract infection. In: The Japanese Journal of Antibiotics. 1985 ; Vol. 38, No. 3. pp. 553-574.

@article{8624870eed8247ebab3e76be0b8b7910,

title = "Clinical studies on TMS-19-Q • o tablet in respiratory tract infection",

abstract = "A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.",

author = "Kohei Hara and Kinichi Izumikawa and Yoji Suzuyama and Yoshiteru Shigeno and Munetaka Komori and Hiroshi Tomita and Masao Sai and Akira Ikebe and Hiromaru Iwasaki and Akira Saito and Masumi Tomizawa and Ichiro Nakayama and Seiichi Aonuma and Kikuo Onuma and Akira Watanabe and Masako Sasaki and Kotaro Oizumi and Kiyoshi Konno and Kosaku Nagai and Izumi Hayashi and Tatsuya Abe and Osamu Sekine and Yoshimaru Usuda and Nobuki Aoki and Yasuko Yuasa and Isao Nitta and Kyoko Watanabe and Fusanosuke Yamasaku and Yasutoshi Suzuki and Masataka Katsu and Shinji Okui and Otohiko Kunii and Takashi Komatsu and Hajime Nishiya and Kohya Shiba and Atsushi Saito and Tadashi Miyahara and Keimei Mashimo and Sumio Yamaoka and Keiichi Nakagawa and Masaru Koyama and Teppei Kumada and Hiroyuki Kobayashi and Hiroaki Takeda and Tomoko Nihei and Mitsuo Obana and Yoshio Kobayashi and Ippei Fujimori and Akira Ito and Masanori Matsumura and Kunihiko Shindo and Kokichi Fukushima and Shigeki Odagiri and Makio Kurihara and Hideyuki Hasegawa and Fumio Matsumoto and Masahito Kato and Joichi Kato and Kazuo Yoshitomo and Motoko Yamamoto and Saburo Kitaura and Hidekazu Hanaki and Yoshiyuki Yamamoto and Toshihiko Takeuchi and Fumio Miki and Kenji Takamatsu and Masakazu Kohno and Yuruko Okamoto and Keigo Maehara and Kanshi Mase and Yube Iida and Muneto Yoshioka and Kojiro Yasunaga and Yoshihiro Ueda and Hiroshi Ohkubo and Rinzo Soejima and Yoshito Niki and Masayoshi Kawanishi and Chikara Nakahama and Masatoshi Watanabe and Jiro Hino and Masakazu Tamura and Toshihiro Goto and Yoshihiro Takishita and Eiro Tsubura and Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Keizo Matsumoto and Yoshio Uzuka and Naoto Rikitomi and Yasutsugu Fukuda and Katsumasa Tokunaga and Masayuki Ando and Haruhiko Tokuomi",

year = "1985",

doi = "10.11553/antibiotics1968b.38.553",

language = "English",

volume = "38",

pages = "553--574",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

number = "3",

}

TY - JOUR

T1 - Clinical studies on TMS-19-Q • o tablet in respiratory tract infection

AU - Hara, Kohei

AU - Izumikawa, Kinichi

AU - Suzuyama, Yoji

AU - Shigeno, Yoshiteru

AU - Komori, Munetaka

AU - Tomita, Hiroshi

AU - Sai, Masao

AU - Ikebe, Akira

AU - Iwasaki, Hiromaru

AU - Saito, Akira

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Aonuma, Seiichi

AU - Onuma, Kikuo

AU - Watanabe, Akira

AU - Sasaki, Masako

AU - Oizumi, Kotaro

AU - Konno, Kiyoshi

AU - Nagai, Kosaku

AU - Hayashi, Izumi

AU - Abe, Tatsuya

AU - Sekine, Osamu

AU - Usuda, Yoshimaru

AU - Aoki, Nobuki

AU - Yuasa, Yasuko

AU - Nitta, Isao

AU - Watanabe, Kyoko

AU - Yamasaku, Fusanosuke

AU - Suzuki, Yasutoshi

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Kunii, Otohiko

AU - Komatsu, Takashi

AU - Nishiya, Hajime

AU - Shiba, Kohya

AU - Saito, Atsushi

AU - Miyahara, Tadashi

AU - Mashimo, Keimei

AU - Yamaoka, Sumio

AU - Nakagawa, Keiichi

AU - Koyama, Masaru

AU - Kumada, Teppei

AU - Kobayashi, Hiroyuki

AU - Takeda, Hiroaki

AU - Nihei, Tomoko

AU - Obana, Mitsuo

AU - Kobayashi, Yoshio

AU - Fujimori, Ippei

AU - Ito, Akira

AU - Matsumura, Masanori

AU - Shindo, Kunihiko

AU - Fukushima, Kokichi

AU - Odagiri, Shigeki

AU - Kurihara, Makio

AU - Hasegawa, Hideyuki

AU - Matsumoto, Fumio

AU - Kato, Masahito

AU - Kato, Joichi

AU - Yoshitomo, Kazuo

AU - Yamamoto, Motoko

AU - Kitaura, Saburo

AU - Hanaki, Hidekazu

AU - Yamamoto, Yoshiyuki

AU - Takeuchi, Toshihiko

AU - Miki, Fumio

AU - Takamatsu, Kenji

AU - Kohno, Masakazu

AU - Okamoto, Yuruko

AU - Maehara, Keigo

AU - Mase, Kanshi

AU - Iida, Yube

AU - Yoshioka, Muneto

AU - Yasunaga, Kojiro

AU - Ueda, Yoshihiro

AU - Ohkubo, Hiroshi

AU - Soejima, Rinzo

AU - Niki, Yoshito

AU - Kawanishi, Masayoshi

AU - Nakahama, Chikara

AU - Watanabe, Masatoshi

AU - Hino, Jiro

AU - Tamura, Masakazu

AU - Goto, Toshihiro

AU - Takishita, Yoshihiro

AU - Tsubura, Eiro

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Matsumoto, Keizo

AU - Uzuka, Yoshio

AU - Rikitomi, Naoto

AU - Fukuda, Yasutsugu

AU - Tokunaga, Katsumasa

AU - Ando, Masayuki

AU - Tokuomi, Haruhiko

PY - 1985

Y1 - 1985

N2 - A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.

AB - A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.

UR - http://www.scopus.com/inward/record.url?scp=0021794127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021794127&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.38.553

DO - 10.11553/antibiotics1968b.38.553

M3 - Article

C2 - 3897599

AN - SCOPUS:0021794127

VL - 38

SP - 553

EP - 574

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

SN - 0368-2781

IS - 3

ER -

Clinical studies on TMS-19-Q • o tablet in respiratory tract infection

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this